G1SecL05: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Moazzam Khan (talk | contribs) No edit summary |
Moazzam Khan (talk | contribs) No edit summary |
||
| Line 12: | Line 12: | ||
==Introduction to LYMErix == | ==Introduction to LYMErix == | ||
LYMErix is a noninfectious vaccine that uses recombinant ospA expressed by ''Escherichia coli'' absorbed into an aluminum hydroxide adjuvant to stimulate immune response during injection. The formation of specific IgG anti- ospA antibodies including those directed towards the epitope LA-2 that resulted following vaccination aimed at traveling to the tick’s mid-gut in order to interact with ''B.burgdorferi'', preventing transmission of Lyme disease to host. | LYMErix is a noninfectious vaccine that uses recombinant ospA expressed by ''Escherichia coli'' absorbed into an aluminum hydroxide adjuvant to stimulate immune response during injection. The formation of specific IgG anti- ospA antibodies including those directed towards the epitope LA-2 that resulted following vaccination aimed at traveling to the tick’s mid-gut in order to interact with ''B.burgdorferi'', preventing transmission of Lyme disease to host. | ||
[[Image:LYMErix.jpg|right|thumb|Retail Packaging of LYMErix]] | |||
==Development of the recombinant vaccine== | ==Development of the recombinant vaccine== | ||
